Exhibit 99.1
INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights
PLYMOUTH MEETING, PA – August 8, 2024 – INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the second quarter of 2024 and provided an update on recent company developments.
“We continue to make progress with our lead candidate, INO-3107, which has the potential to significantly improve the lives of patients with RRP. We expect all non-device related elements of our BLA package to be completed by year end and our pre-BLA meeting last week with the FDA provided us with confidence that we remain on the right track for the regulatory submission. However, as part of the testing process required for BLA submission, we’ve recently identified a manufacturing issue with the single use disposable administration component of our device that we believe is resolvable, but will take additional time to rectify,” said Dr. Jacqueline Shea, INOVIO’s President and Chief Executive Officer. “We’re taking corrective steps to address the issue, and while we have not altered our ultimate expectations for INO-3107 to be a potentially transformative therapeutic option for RRP patients that could be the first DNA medicine approved for use in the United States, we now expect to be able to submit the BLA in mid-2025. We will continue to work hard to advance all other elements necessary for INO-3107’s success, including working to initiate our confirmatory trial, advancing plans for our redosing trial, making key regulatory progress in Europe and the U.K., and continuing commercial preparations to be launch-ready if we receive approval. These efforts will help maintain the momentum that’s carried us from Breakthrough Therapy Designation to BLA preparation in less than a year.”
“We’ve continued making progress in other key areas of our business as well,” Dr. Shea continued. “We submitted our Phase 3 clinical plans for INO-3112 to European regulatory authorities, anticipate re-submitting our Phase 2 clinical plans for our Ebola booster vaccine candidate, INO-4201, to the FDA in the third quarter, and are continuing discussions with partners to advance INO-5401 as a potential treatment for GBM. We also welcomed Steve Egge to our leadership team as our Chief Commercial Officer. Steve brings extensive launch experience in HPV-related diseases, cancer, immunology and rare diseases and I know his commercial expertise will be invaluable as we work to advance INO-3107 and our other promising candidates.”
Recent Business Highlights
INO-3107 – Recurrent Respiratory Papillomatosis (RRP)
| • | INOVIO continued advancing preparations for submitting its BLA under the FDA’s Accelerated Approval pathway, including holding a pre-BLA meeting with the FDA, advancing development of all BLA modules, trial site preparations and ongoing commercial readiness plans. However, INOVIO has identified an issue related to the manufacturing of the single use disposable administration component of the CELLECTRA® device that will delay its BLA submission, now anticipated in mid-2025. INOVIO is working to rectify the issue as quickly as possible, using all resources available, and expects to provide further updates at the next quarterly report. |
| • | INO-3107 was designated an innovative medicine as part of the U.K.’s Innovative Licensing and Access Pathway (ILAP). The designation, called an Innovation Passport, is the first step on a development pathway that offers enhanced access to regulators and development tools that could accelerate the timeline for achieving U.K. regulatory approval. |
| • | INO-3107 received an Advanced Therapy Medicinal Product (ATMP) Certification from the European Medicines Agency’s Committee for Advanced Therapies (CAT) after review of chemistry, manufacturing and controls (CMC) and nonclinical data. This certification confirms that the data reviewed complies with the standards that would be used to evaluate a European marketing-authorization application. |
| • | Immunology data for INO-3107 has been accepted at the following fourth quarter conferences: |
| • | Fall Voice, a leading conference for clinicians focused on vocal disorders |
| • | 36th International Papillomavirus Conference, a platform for sharing cutting-edge international HPV research |
| • | International Society for Vaccines Annual Congress |
INO-3112 – Oropharyngeal Squamous Cell Carcinoma (OPSCC)
| • | INOVIO submitted its Phase 3 trial design for INO-3112 to European regulatory authorities. The proposed multi-center Phase 3 trial will investigate INO-3112 in combination with LOQTORZI as a potential treatment for oropharyngeal squamous cell carcinoma (OPSCC). INOVIO plans to conduct the trial in Europe and North America. INOVIO received positive feedback on this study protocol from the FDA in the first quarter of 2024. The manufacturing issue with the single use disposable administration component of the device that is impacting INO-3107 will also need to be resolved before we can commence the Phase 3 trial with INO-3112. |
| • | The combination of INO-3112 with LOQTORZI has the potential to address a substantial unmet need in patients with HPV-16 and -18 related high-risk throat cancer. The Phase 3 study will investigate whether LOQTORZI can help amplify the tumor-infiltrating abilities of the antigen-specific T cells generated by INO-3112. INO-3112 is a DNA medicine candidate containing a DNA plasmid encoding HPV-16/-18 E6 and E7 antigens combined with another DNA plasmid encoding IL-12 as an immune activator. LOQTORZI is an FDA-approved PD-1 inhibitor approved for the treatment of recurrent locally advanced/metastatic nasopharyngeal carcinoma. |
INO-4201 for Ebola
| • | INOVIO anticipates submitting its revised protocol to the FDA for a Phase 2/3 clinical trial with INO-4201 as a heterologous boost to the FDA licensed Ebola vaccine, Ervebo, in the third quarter. INOVIO previously announced positive results from a Phase 1b clinical trial evaluating INO-4201 as a booster in healthy adult participants who previously received a single injection of Ervebo. In the trial, INO-4201 was well-tolerated and boosted humoral responses in 100% (36 of 36) of treated participants. |
Operational and Financial Updates
| • | INOVIO appointed Steve Egge as Chief Commercial Officer to lead the company’s commercial strategy and operations as it prepares to launch INO-3107. Mr. Egge has extensive experience in many different therapeutic areas, including immunology and vaccines, HPV, and rare disease. Mr. Egge spent 20 years at Merck, where he held a number of different commercial leadership roles, including leading Merck’s HPV Vaccines Franchise and serving as Chief Marketing Officer for the Vaccine Division. Over the course of his career, he has overseen or contributed to more than 13 commercial product launches. INOVIO welcomes his expertise, particularly in creating and growing new therapeutic areas as well as driving market share in competitive markets. |
| • | INOVIO strengthened its balance sheet with an offering of common stock and pre-funded warrants in April 2024; net proceeds from the offering, after deducting underwriting discounts and commissions and offering expenses, were $33.2 million. |
Second Quarter 2024 Financial Results
| • | Cash, Cash Equivalents and Short-term Investments: As of June 30, 2024, cash, cash equivalents and short-term investments were $110.4 million compared to $145.3 million as of December 31, 2023. |
| • | Research and Development (R&D) Expenses: R&D expenses for the three months ended June 30, 2024, were $23.1 million compared to $23.7 million for the same period in 2023. The slight decrease in R&D expenses was primarily the result of overall lower drug manufacturing costs and lower employee and consultant compensation, including non-cash stock-based compensation, among other variances. |
| • | General and Administrative (G&A) Expenses: G&A expenses were $10.2 million for the three months ended June 30, 2024 compared to $13.5 million for the same period in 2023. The decrease in G&A expenses was primarily related to a decrease in employee compensation, including non-cash employee and consultant stock-based compensation, and a decrease in legal expenses, among other variances. |
| • | Total Operating Expenses: Total operating expenses were $33.3 million for the three months ended June 30, 2024, compared to $37.3 million for the same period in 2023. |
| • | Net Loss: INOVIO’s net loss for the three months ended June 30, 2024 was $32.2 million, or $1.19 per basic and diluted share, compared to net loss of $35.5 million, or $1.61 per basic and diluted share, for the three months ended June 30, 2023. |
| • | Shares Outstanding: As of June 30, 2024, INOVIO had 26.0 million common shares outstanding, 2.1 million pre-funded warrants outstanding, and 29.9 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting, and conversion, as applicable, of its outstanding pre-funded warrants, options, restricted stock units and convertible preferred stock. |
INOVIO’s balance sheet and statement of operations are provided below. Additional information is included in INOVIO’s quarterly report on Form 10-Q for the quarter ended June 30, 2024, which can be accessed at: http://ir.inovio.com/financials/default.aspx.
Cash Guidance
INOVIO estimates its cash runway to extend into the third quarter of 2025. This projection includes an operational net cash burn estimate of approximately $28 million for the third quarter of 2024. These cash runway projections do not include any further capital-raising activities that INOVIO may undertake.
Conference Call / Webcast Information
INOVIO’s management will host a live conference call and webcast with slides at 4:30 p.m. ET today to discuss INOVIO’s financial results and provide a general business update. The live webcast and replay may be accessed by visiting INOVIO’s website at http://ir.inovio.com/events-and-presentations/default.aspx.
About INOVIO’s DNA Medicines Platform
INOVIO’s DNA medicines platform has two innovative components: precisely designed DNA plasmids, delivered by INOVIO’s proprietary investigational medical device, CELLECTRA®. INOVIO uses proprietary technology to design its DNA plasmids, which are small circular DNA molecules that work like software the body’s cells can download to produce specific proteins to target and fight disease. INOVIO’s proprietary CELLECTRA® delivery devices are designed to optimally deliver its DNA medicines to the body’s cells without requiring chemical adjuvants or lipid nanoparticles and without the risk of the anti-vector response historically seen with viral vector platforms.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO’s technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contact:
Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Thomas Hong (267) 440-4298 thomas.hong@inovio.com
Forward-Looking Statements
This press release contains certain forward-looking statements relating to our business, including our plans to develop and commercialize DNA medicines and our expectations regarding our research and development programs, including the planned initiation and conduct of clinical trials and the availability and timing of data from those trials, the planned submission of a BLA towards the middle of 2025, plans for discussions with regulatory authorities, the planned commercial launch of INO-3107 if regulatory approval is obtained, and expectations with respect to our cash resources into the third quarter of 2025 and expected cash burn for the third quarter of 2024. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials, product development programs and commercialization activities and outcomes, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2023, our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured, or commercialized, that the results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.
Inovio Pharmaceuticals, Inc.
CONSOLIDATED BALANCE SHEETS
| June 30, 2024 |
December 31, 2023 |
|||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 34,392,404 | $ | 14,310,862 | ||||
| Short-term investments |
76,029,116 | 130,982,913 | ||||||
| Accounts receivable from affiliated entities |
1,773,665 | 2,405,228 | ||||||
| Prepaid expenses and other current assets |
5,365,860 | 5,393,665 | ||||||
| Prepaid expenses and other current assets from affiliated entities |
— | 20,432 | ||||||
|
|
|
|
|
|||||
| Total current assets |
117,561,045 | 153,113,100 | ||||||
| Fixed assets, net |
4,510,869 | 4,960,986 | ||||||
| Investment in affiliated entity |
2,319,975 | 2,780,287 | ||||||
| Operating lease right-of-use assets |
8,819,399 | 9,491,735 | ||||||
| Other assets |
585,915 | 605,315 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 133,797,203 | $ | 170,951,423 | ||||
|
|
|
|
|
|||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: |
||||||||
| Accounts payable and accrued expenses |
$ | 16,634,761 | $ | 19,847,744 | ||||
| Accounts payable and accrued expenses due to affiliated entity |
1,921,457 | 1,070,519 | ||||||
| Accrued clinical trial expenses |
5,499,648 | 2,365,382 | ||||||
| Operating lease liability |
2,321,984 | 2,406,522 | ||||||
| Grant funding liability |
— | 87,489 | ||||||
| Grant funding liability from affiliated entity |
21,918 | 21,918 | ||||||
| Convertible senior notes |
— | 16,770,654 | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
26,399,768 | 42,570,228 | ||||||
| Operating lease liability, net of current portion |
10,658,228 | 11,032,066 | ||||||
|
|
|
|
|
|||||
| Total liabilities |
37,057,996 | 53,602,294 | ||||||
|
|
|
|
|
|||||
| Stockholders’ equity: |
||||||||
| Preferred stock |
— | — | ||||||
| Common stock |
25,962 | 22,792 | ||||||
| Additional paid-in capital |
1,783,074,886 | 1,740,954,074 | ||||||
| Accumulated deficit |
(1,685,672,105 | ) | (1,622,965,136 | ) | ||||
| Accumulated other comprehensive loss |
(689,536 | ) | (662,601 | ) | ||||
|
|
|
|
|
|||||
| Total Inovio Pharmaceuticals, Inc. stockholders’ equity |
96,739,207 | 117,349,129 | ||||||
|
|
|
|
|
|||||
| Total liabilities and stockholders’ equity |
$ | 133,797,203 | $ | 170,951,423 | ||||
|
|
|
|
|
|||||
Inovio Pharmaceuticals, Inc.
CONSOLIDATED STATEMENTS OF OPERATIONS
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Revenue from collaborative arrangements and other contracts |
$ | 100,762 | $ | 225,971 | $ | 100,762 | $ | 340,914 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Operating expenses: |
||||||||||||||||
| Research and development |
23,090,989 | 23,743,970 | 44,001,307 | 53,920,481 | ||||||||||||
| General and administrative |
10,206,686 | 13,523,098 | 20,781,337 | 27,413,708 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total operating expenses |
33,297,675 | 37,267,068 | 64,782,644 | 81,334,189 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Loss from operations |
(33,196,913 | ) | (37,041,097 | ) | (64,681,882 | ) | (80,993,275 | ) | ||||||||
| Other income (expense): |
||||||||||||||||
| Interest income |
1,307,358 | 2,168,233 | 2,807,648 | 4,375,404 | ||||||||||||
| Interest expense |
— | (313,488 | ) | (177,833 | ) | (626,976 | ) | |||||||||
| (Loss) gain on investment in affiliated entity |
(334,294 | ) | 156,745 | (460,312 | ) | 773,384 | ||||||||||
| Net unrealized (loss) gain on available-for-sale equity securities |
(20,820 | ) | 922,941 | 480,057 | 4,141,156 | |||||||||||
| Other income (expense), net |
7,571 | (1,427,867 | ) | (674,647 | ) | (3,853,543 | ) | |||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss |
$ | (32,237,098 | ) | $ | (35,534,533 | ) | $ | (62,706,969 | ) | $ | (76,183,850 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss per share |
||||||||||||||||
| Basic and diluted (1) |
$ | (1.19 | ) | $ | (1.61 | ) | $ | (2.48 | ) | $ | (3.50 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Weighted average number of common shares used to compute net loss per share |
||||||||||||||||
| Basic and diluted (1) |
27,197,802 | 22,029,486 | 25,244,657 | 21,784,343 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| (1) | Share and per share amounts have been restated to reflect the 1-for-12 reverse stock split effected in January 2024 on a retroactive basis for all periods presented. |